Overview

Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Dexlansoprazole
Lansoprazole